3 ms·
This happened to Otonomy about a year ago and their stock fell off a cliff. The interesting thing with them was that they were doing 2 sets of phase 3 trials: o
by patorjk 8y ago
This happened to Otonomy about a year ago and their stock fell off a cliff. The interesting thing with them was that they were doing 2 sets of phase 3 trials: one in the US, and one in Europe. A little while after the US one failed, the data from the European one came out and showed statistical significance. I remember reading that some of the scientists at Otonomy believed the problem with the US study was that some of the doctors who were administering the drug were telling the patients that it really worked, because the success for placebo patents was higher in the US than it was in Europe.
- refurb 8y agoA lot of people underestimate the challenge of running a clinical trial. Clinical trials are often run across multiple sites/countries where medical standards differ. The placebo effect can be brutal particularly in the more subjective trial endpoints. People crap all over the anti-depressant clinical trial data, but guess what? It's a poster boy for the placebo effect and trying to development objective endpoints you can measure.